Treatment of Vision Loss in Giant Cell Arteritis

Opinion statement If giant cell arteritis is suspected as a cause of visual loss, emergent management is necessary. Clinical suspicion should prompt the practitioner to obtain laboratory studies and initiate treatment prior to establishing the diagnosis. The evaluation includes immediate erythrocyte...

Full description

Saved in:
Bibliographic Details
Published in:Current treatment options in neurology 2012-02, Vol.14 (1), p.84-92
Main Authors: Scheurer, Ryan A., Harrison, Andrew R., Lee, Michael S.
Format: Article
Language:English
Subjects:
Critical Care Medicine
Diabetes
Family Medicine
General Practice
Intensive
Internal Medicine
Medicine
Medicine & Public Health
Neurologic Ophthalmology and Otology (RK Shin
Neurology
Ophthalmology
Section Editor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c435t-2fab237b05804ca88e62a53c7d706caa1d5101ff70fbcb8cbfd7112e14bf33883
cites cdi_FETCH-LOGICAL-c435t-2fab237b05804ca88e62a53c7d706caa1d5101ff70fbcb8cbfd7112e14bf33883
container_end_page 92
container_issue 1
container_start_page 84
container_title Current treatment options in neurology
container_volume 14
creator Scheurer, Ryan A.
Harrison, Andrew R.
Lee, Michael S.
description Opinion statement If giant cell arteritis is suspected as a cause of visual loss, emergent management is necessary. Clinical suspicion should prompt the practitioner to obtain laboratory studies and initiate treatment prior to establishing the diagnosis. The evaluation includes immediate erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and complete blood count (CBC). Treatment begins with high-dose intravenous corticosteroids. We recommend intravenous methylprednisolone (250 mg every 6 h) for 3 to 5 days. During that time, a temporal artery biopsy should be performed for pathologic diagnosis. We also begin daily adjunctive aspirin orally. After the initial bolus of intravenous corticosteroids, therapy transitions to oral prednisone administered at 1 mg/kg per day until the activity of the disease process attenuates, as demonstrated by improvement in systemic symptoms and normalization of both ESR and CRP. This change usually occurs in the first 3 to 4 weeks. The patient should be followed closely, with therapy tapered as guided by systemic symptoms, ESR, and CRP. To maximize the use of remaining vision, appropriate patients should be referred to specialists for help with low-vision therapies, assistive devices, and precautions to protect the better-seeing eye.
doi_str_mv 10.1007/s11940-011-0152-7
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_916527999</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>916527999</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-2fab237b05804ca88e62a53c7d706caa1d5101ff70fbcb8cbfd7112e14bf33883</originalsourceid><addsrcrecordid>eNp9kMFOwzAMhiMEYmPwAFxQb5wKdtIs6XGaYCBV4jK4RmmaoExrO5L2wNuTqYMjB8uW_fuX_RFyi_CAAOIxIpYF5ICYgtNcnJE5clbkDJk8TzWUNJeFhBm5inEHQHmBeElmlAITZSnnBLbB6qG13ZD1Lvvw0fddVvUxZr7LNl6n_tru99kqDDb4wcdrcuH0PtqbU16Q9-en7folr942r-tVlZuC8SGnTteUiRq4hMJoKe2Sas6MaAQsjdbYcAR0ToCrTS1N7RqBSC0WtWNMSrYg95PvIfRfo42Dan006RTd2X6MqsQlp-mHMilxUpqQ7g7WqUPwrQ7fCkEdOamJk0qc1JGTEmnn7uQ-1q1t_jZ-wSQBnQQxjbpPG9SuH0OXPv7H9QfVLXF9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>916527999</pqid></control><display><type>article</type><title>Treatment of Vision Loss in Giant Cell Arteritis</title><source>Springer Link</source><creator>Scheurer, Ryan A. ; Harrison, Andrew R. ; Lee, Michael S.</creator><creatorcontrib>Scheurer, Ryan A. ; Harrison, Andrew R. ; Lee, Michael S.</creatorcontrib><description>Opinion statement If giant cell arteritis is suspected as a cause of visual loss, emergent management is necessary. Clinical suspicion should prompt the practitioner to obtain laboratory studies and initiate treatment prior to establishing the diagnosis. The evaluation includes immediate erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and complete blood count (CBC). Treatment begins with high-dose intravenous corticosteroids. We recommend intravenous methylprednisolone (250 mg every 6 h) for 3 to 5 days. During that time, a temporal artery biopsy should be performed for pathologic diagnosis. We also begin daily adjunctive aspirin orally. After the initial bolus of intravenous corticosteroids, therapy transitions to oral prednisone administered at 1 mg/kg per day until the activity of the disease process attenuates, as demonstrated by improvement in systemic symptoms and normalization of both ESR and CRP. This change usually occurs in the first 3 to 4 weeks. The patient should be followed closely, with therapy tapered as guided by systemic symptoms, ESR, and CRP. To maximize the use of remaining vision, appropriate patients should be referred to specialists for help with low-vision therapies, assistive devices, and precautions to protect the better-seeing eye.</description><identifier>ISSN: 1092-8480</identifier><identifier>EISSN: 1534-3138</identifier><identifier>DOI: 10.1007/s11940-011-0152-7</identifier><identifier>PMID: 22037998</identifier><language>eng</language><publisher>New York: Current Science Inc</publisher><subject>Critical Care Medicine ; Diabetes ; Family Medicine ; General Practice ; Intensive ; Internal Medicine ; Medicine ; Medicine &amp; Public Health ; Neurologic Ophthalmology and Otology (RK Shin ; Neurology ; Ophthalmology ; Section Editor</subject><ispartof>Current treatment options in neurology, 2012-02, Vol.14 (1), p.84-92</ispartof><rights>Springer Science+Business Media, LLC 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-2fab237b05804ca88e62a53c7d706caa1d5101ff70fbcb8cbfd7112e14bf33883</citedby><cites>FETCH-LOGICAL-c435t-2fab237b05804ca88e62a53c7d706caa1d5101ff70fbcb8cbfd7112e14bf33883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22037998$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scheurer, Ryan A.</creatorcontrib><creatorcontrib>Harrison, Andrew R.</creatorcontrib><creatorcontrib>Lee, Michael S.</creatorcontrib><title>Treatment of Vision Loss in Giant Cell Arteritis</title><title>Current treatment options in neurology</title><addtitle>Curr Treat Options Neurol</addtitle><addtitle>Curr Treat Options Neurol</addtitle><description>Opinion statement If giant cell arteritis is suspected as a cause of visual loss, emergent management is necessary. Clinical suspicion should prompt the practitioner to obtain laboratory studies and initiate treatment prior to establishing the diagnosis. The evaluation includes immediate erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and complete blood count (CBC). Treatment begins with high-dose intravenous corticosteroids. We recommend intravenous methylprednisolone (250 mg every 6 h) for 3 to 5 days. During that time, a temporal artery biopsy should be performed for pathologic diagnosis. We also begin daily adjunctive aspirin orally. After the initial bolus of intravenous corticosteroids, therapy transitions to oral prednisone administered at 1 mg/kg per day until the activity of the disease process attenuates, as demonstrated by improvement in systemic symptoms and normalization of both ESR and CRP. This change usually occurs in the first 3 to 4 weeks. The patient should be followed closely, with therapy tapered as guided by systemic symptoms, ESR, and CRP. To maximize the use of remaining vision, appropriate patients should be referred to specialists for help with low-vision therapies, assistive devices, and precautions to protect the better-seeing eye.</description><subject>Critical Care Medicine</subject><subject>Diabetes</subject><subject>Family Medicine</subject><subject>General Practice</subject><subject>Intensive</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Neurologic Ophthalmology and Otology (RK Shin</subject><subject>Neurology</subject><subject>Ophthalmology</subject><subject>Section Editor</subject><issn>1092-8480</issn><issn>1534-3138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp9kMFOwzAMhiMEYmPwAFxQb5wKdtIs6XGaYCBV4jK4RmmaoExrO5L2wNuTqYMjB8uW_fuX_RFyi_CAAOIxIpYF5ICYgtNcnJE5clbkDJk8TzWUNJeFhBm5inEHQHmBeElmlAITZSnnBLbB6qG13ZD1Lvvw0fddVvUxZr7LNl6n_tru99kqDDb4wcdrcuH0PtqbU16Q9-en7folr942r-tVlZuC8SGnTteUiRq4hMJoKe2Sas6MaAQsjdbYcAR0ToCrTS1N7RqBSC0WtWNMSrYg95PvIfRfo42Dan006RTd2X6MqsQlp-mHMilxUpqQ7g7WqUPwrQ7fCkEdOamJk0qc1JGTEmnn7uQ-1q1t_jZ-wSQBnQQxjbpPG9SuH0OXPv7H9QfVLXF9</recordid><startdate>20120201</startdate><enddate>20120201</enddate><creator>Scheurer, Ryan A.</creator><creator>Harrison, Andrew R.</creator><creator>Lee, Michael S.</creator><general>Current Science Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120201</creationdate><title>Treatment of Vision Loss in Giant Cell Arteritis</title><author>Scheurer, Ryan A. ; Harrison, Andrew R. ; Lee, Michael S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-2fab237b05804ca88e62a53c7d706caa1d5101ff70fbcb8cbfd7112e14bf33883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Critical Care Medicine</topic><topic>Diabetes</topic><topic>Family Medicine</topic><topic>General Practice</topic><topic>Intensive</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Neurologic Ophthalmology and Otology (RK Shin</topic><topic>Neurology</topic><topic>Ophthalmology</topic><topic>Section Editor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scheurer, Ryan A.</creatorcontrib><creatorcontrib>Harrison, Andrew R.</creatorcontrib><creatorcontrib>Lee, Michael S.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current treatment options in neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scheurer, Ryan A.</au><au>Harrison, Andrew R.</au><au>Lee, Michael S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Vision Loss in Giant Cell Arteritis</atitle><jtitle>Current treatment options in neurology</jtitle><stitle>Curr Treat Options Neurol</stitle><addtitle>Curr Treat Options Neurol</addtitle><date>2012-02-01</date><risdate>2012</risdate><volume>14</volume><issue>1</issue><spage>84</spage><epage>92</epage><pages>84-92</pages><issn>1092-8480</issn><eissn>1534-3138</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Opinion statement If giant cell arteritis is suspected as a cause of visual loss, emergent management is necessary. Clinical suspicion should prompt the practitioner to obtain laboratory studies and initiate treatment prior to establishing the diagnosis. The evaluation includes immediate erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and complete blood count (CBC). Treatment begins with high-dose intravenous corticosteroids. We recommend intravenous methylprednisolone (250 mg every 6 h) for 3 to 5 days. During that time, a temporal artery biopsy should be performed for pathologic diagnosis. We also begin daily adjunctive aspirin orally. After the initial bolus of intravenous corticosteroids, therapy transitions to oral prednisone administered at 1 mg/kg per day until the activity of the disease process attenuates, as demonstrated by improvement in systemic symptoms and normalization of both ESR and CRP. This change usually occurs in the first 3 to 4 weeks. The patient should be followed closely, with therapy tapered as guided by systemic symptoms, ESR, and CRP. To maximize the use of remaining vision, appropriate patients should be referred to specialists for help with low-vision therapies, assistive devices, and precautions to protect the better-seeing eye.</abstract><cop>New York</cop><pub>Current Science Inc</pub><pmid>22037998</pmid><doi>10.1007/s11940-011-0152-7</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1092-8480
ispartof Current treatment options in neurology, 2012-02, Vol.14 (1), p.84-92
issn 1092-8480
1534-3138
language eng
recordid cdi_proquest_miscellaneous_916527999
source Springer Link
subjects Critical Care Medicine
Diabetes
Family Medicine
General Practice
Intensive
Internal Medicine
Medicine
Medicine & Public Health
Neurologic Ophthalmology and Otology (RK Shin
Neurology
Ophthalmology
Section Editor
title Treatment of Vision Loss in Giant Cell Arteritis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T09%3A19%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Vision%20Loss%20in%20Giant%20Cell%20Arteritis&rft.jtitle=Current%20treatment%20options%20in%20neurology&rft.au=Scheurer,%20Ryan%20A.&rft.date=2012-02-01&rft.volume=14&rft.issue=1&rft.spage=84&rft.epage=92&rft.pages=84-92&rft.issn=1092-8480&rft.eissn=1534-3138&rft_id=info:doi/10.1007/s11940-011-0152-7&rft_dat=%3Cproquest_cross%3E916527999%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c435t-2fab237b05804ca88e62a53c7d706caa1d5101ff70fbcb8cbfd7112e14bf33883%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=916527999&rft_id=info:pmid/22037998&rfr_iscdi=true